BidaskClub upgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from a hold rating to a buy rating in a report released on Saturday.
A number of other brokerages have also recently issued reports on KERX. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the company a buy rating in a report on Thursday, May 10th. ValuEngine cut shares of Keryx Biopharmaceuticals from a sell rating to a strong sell rating in a report on Wednesday, May 9th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a sell rating to a hold rating in a report on Wednesday, April 11th. Finally, Morgan Stanley lowered their target price on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an equal weight rating on the stock in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $7.19.
Shares of KERX stock opened at $5.82 on Friday. The company has a current ratio of 3.12, a quick ratio of 2.49 and a debt-to-equity ratio of -8.87. Keryx Biopharmaceuticals has a 1 year low of $5.60 and a 1 year high of $5.88. The firm has a market cap of $668.46 million, a price-to-earnings ratio of -6.61 and a beta of 2.57.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). Keryx Biopharmaceuticals had a negative net margin of 230.00% and a negative return on equity of 1,452.76%. The business had revenue of $21.75 million for the quarter, compared to analysts’ expectations of $21.80 million. sell-side analysts expect that Keryx Biopharmaceuticals will post -0.61 EPS for the current fiscal year.
In other news, CFO Scott A. Holmes sold 5,651 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $4.81, for a total value of $27,181.31. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Brian Adams sold 5,652 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total transaction of $27,186.12. The disclosure for this sale can be found here. Insiders have sold a total of 33,476 shares of company stock worth $160,295 in the last three months. Insiders own 2.58% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its holdings in shares of Keryx Biopharmaceuticals by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 164,003 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 13,676 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Keryx Biopharmaceuticals by 3.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 536,951 shares of the biopharmaceutical company’s stock worth $2,197,000 after purchasing an additional 17,620 shares during the period. Swiss National Bank increased its holdings in shares of Keryx Biopharmaceuticals by 13.0% in the first quarter. Swiss National Bank now owns 160,600 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 18,500 shares during the period. Geode Capital Management LLC increased its holdings in shares of Keryx Biopharmaceuticals by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 912,179 shares of the biopharmaceutical company’s stock worth $4,241,000 after purchasing an additional 19,003 shares during the period. Finally, Teacher Retirement System of Texas bought a new position in shares of Keryx Biopharmaceuticals in the fourth quarter worth $142,000. 65.10% of the stock is currently owned by hedge funds and other institutional investors.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.